体质量指数与淋巴瘤患者的生存。
Body mass index and survival of patients with lymphoma.
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
出版信息
Leuk Lymphoma. 2021 Nov;62(11):2671-2678. doi: 10.1080/10428194.2021.1929956. Epub 2021 Jun 14.
The impact of body mass index (BMI) on survival in lymphoma remains controversial. We leveraged a prospective cohort of lymphoma patients enrolled to SPORE Molecular Epidemiology Resource between 2002 and 2015 to assess the association of BMI before diagnosis, BMI at diagnosis, and BMI change over time with lymphoma-specific survival (LSS). A total of 4009 lymphoma patients (670 diffuse large B-cell lymphoma (DLBCL), 689 follicular lymphoma (FL), 1018 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and 1632 other subtypes) were included. Significantly shorter LSS after diagnosis was observed for FL patients who were obese before diagnosis (HR: 3.02, 95%CI: 1.43-6.41, =.004) and for those with ≥ 5% increase in BMI from diagnosis to 3-year follow-up (HR: 3.53, 95%CI: 1.22-10.2, =.020). In contrast, obesity prior to or at the time of diagnosis was not associated with LSS in DLBCL and CLL/SLL. The impact of weight control after diagnosis in FL patient warrants investigation.
体重指数（BMI）对淋巴瘤患者生存的影响仍存在争议。我们利用了 2002 年至 2015 年期间纳入 SPORE 分子流行病学资源的前瞻性淋巴瘤患者队列，评估诊断前 BMI、诊断时 BMI 和随时间变化的 BMI 与淋巴瘤特异性生存（LSS）之间的关联。共纳入 4009 例淋巴瘤患者（670 例弥漫性大 B 细胞淋巴瘤（DLBCL）、689 例滤泡淋巴瘤（FL）、1018 例慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）和 1632 例其他亚型）。诊断后 FL 患者的 LSS 明显缩短，诊断前肥胖患者（HR：3.02，95%CI：1.43-6.41，P =.004）和 BMI 从诊断到 3 年随访时增加≥5%的患者（HR：3.53，95%CI：1.22-10.2，P =.020）。相比之下，DLBCL 和 CLL/SLL 患者诊断前或诊断时的肥胖与 LSS 无关。需要进一步研究 FL 患者诊断后体重控制对其预后的影响。
Zotero 插件